Skip to content

Effectiveness and safety of defocusing lens based on Bionic-Compound Multifocal Defocus (B.C.M.D.) technology in delaying the progression of myopia

Effectiveness and safety of defocusing lens based on Bionic-Compound Multifocal Defocus (B.C.M.D.) technology in delaying the progression of myopia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063972
Enrollment
Unknown
Registered
2022-09-22
Start date
2022-09-22
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ametropia

Interventions

Experimental group: Wear defocus frame glasses

Sponsors

Tianjin Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 13 Years

Inclusion criteria

Inclusion criteria: 1. Aged 8-13 years, no gender limit; 2. The spherical power of ametropia after bilateral ciliary muscle paralysis ranges from -1.00D to -5.00D; 3. Astigmatism = 1.0; 6. Both eyes are normal eyes without other abnormalities or diseases except ametropia.

Exclusion criteria

Exclusion criteria: 1. Contraindicated wearing frame glasses for any systemic disease or drug therapy for disease will affect vision; 2. Patients with ocular trauma or surgical history within 8 weeks prior to inclusion in this test; 3. Participant in other clinical tests; 4. Have used or are using specially designed myopia control lenses (including frames and contact lenses) and atropine drugs within one year.

Design outcomes

Primary

MeasureTime frame
Computer optometry equivalent spherical under ciliary muscle paralysis;

Secondary

MeasureTime frame
Axial lengths;

Countries

China

Contacts

Public ContactLi Lihua
lilihua5081@vip.sina.com+86 13752007098

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026